4-环丙基-2-(三氟甲基)-5-嘧啶羧酸 | 914201-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-环丙基-2-(三氟甲基)-5-嘧啶羧酸
• 中文别名: 4-环丙基-2-三氟甲基嘧啶-5-甲酸
• 英文名称: 4-cyclopropyl-2-(trifluoromethyl)pyrimidine-5-carboxylic acid
• CAS: 914201-19-7
• 化学式: C₉H₇F₃N₂O₂
• 分子量: 232.162
• InChiKey: ZESNFMDGMALERE-UHFFFAOYSA-N

物化性质

• 沸点：
  262.0±40.0 °C(Predicted)
• 密度：
  1.548±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 海关编码：
  2933599090

文献信息

• OXAZOLINE DERIVATIVES
  申请人：Galley Guido

  公开号：US20110112080A1

  公开（公告）日：2011-05-12

  The invention relates to compounds of formula I wherein the definitions of X, R and R 1 are as defined herein. The compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及公式I中的化合物，其中X、R和R1的定义如本文所述。公式I中的化合物对痕量胺相关受体（TAARs）有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、躁郁症、注意力缺陷多动障碍（ADHD）、与压力相关的障碍、精神分裂症等精神障碍、帕金森病等神经疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢性障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病。
• Dpp-IV inhibitors
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP2019099A1

  公开（公告）日：2009-01-28

  The invention relates to compounds of formula (I) wherein R1, R2, R3 and n have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament.

  本发明涉及式（I）化合物，其中R1、R2、R3和n的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。本发明还涉及制备这种化合物以及将其作为药物的生产和使用。
• PIPERIDINE DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130158050A1

  公开（公告）日：2013-06-20

  The present invention relates to a compound of formula I wherein R 1 , R 2 , and Ar are as defined herein or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. These compounds and their pharmaceutical compositions are useful in the treatment of neurological and neuropsychiatric disorders.

  本发明涉及一种化合物I的配方，其中R1，R2和Ar的定义如本文所述，或者是其对应的外消旋混合物、对映体和/或光学异构体的药学上可接受的酸加盐。这些化合物及其制药组合物在神经系统和神经精神疾病的治疗中有用。
• AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2391603B1

  公开（公告）日：2014-01-08
• OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS.
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2499121B1

  公开（公告）日：2015-10-07